Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 19, 2025SAGE Open MedicineOpen Access

Acute heart failure in patients with hematologic malignancies: A nationwide analysis 2016–2021

View Full Paper
Ask AI
Bookmark
Share

Authors

BSBarath Prashanth SivasubramanianBSBarath Prashanth SivasubramanianSYSiva Naga S. Yarrarapu

Discussion

Loading...

Member takes

Overview

Analysis reveals in-hospital mortality patterns in patients with hematological malignancies, suggesting acute heart failure influences outcomes.

Key Points

  • Acute heart failure was linked to an 8.08% in-hospital mortality rate in patients with hematological malignancies, higher than the 4.52% of the non-acute group.
  • The study found a lower mortality risk associated with acute heart failure when adjusted for sociodemographic factors and comorbidities, with an odds ratio of 0.87.
  • Multivariate regression analysis identified age over 60 years and severe sepsis as additional predictors of mortality in the acute heart failure cohort.
  • Subgroup analysis indicated that patients with acute myeloid leukemia and chronic lymphocytic leukemia exhibited higher mortality in the acute heart failure group.

Cite This Study

Sivasubramanian et al. (2025) studied this question.

synapsesocial.com/papers/68f57402e45510db9c80ec56https://doi.org/10.1177/20503121251370940
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review2024 · 7 citations
  2. 2Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms2024 · 14 citations
  3. 3Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy2017 · 61 citations
  4. 4Atrial Fibrillation and Heart Failure2022 · 44 citations
  5. 52022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)2022 · 3,064 citations